Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

Deepika Kanojia, Manoj Garg, Jacqueline Martinez, M. T. Anand, Samuel B. Luty, Ngan B. Doan, Jonathan W. Said, Charles Forscher, Jeffrey Tyner, H. Phillip Koeffler

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are excellent therapeutic targets. However, very limited knowledge exists of therapeutic critical kinase targets in liposarcoma that could be potentially used in disease management. Methods: Large RNAi and small-molecule tyrosine kinase inhibitor screens were performed against the proliferative capacity of liposarcoma cell lines of different subtypes. Each small molecule inhibitor was either FDA approved or in a clinical trial. Results: Screening assays identified several previously unrecognized targets including PTK2 and KIT in liposarcoma. We also observed that ponatinib, multi-targeted tyrosine kinase inhibitor, was the most effective drug with anti-growth effects against all cell lines. In vitro assays showed that ponatinib inhibited the clonogenic proliferation of liposarcoma, and this anti-growth effect was associated with apoptosis and cell cycle arrest at the G0/G1 phase as well as a decrease in the KIT signaling pathway. In addition, ponatinib inhibited in vivo growth of liposarcoma in a xenograft model. Conclusions: Two large-scale kinase screenings identified novel liposarcoma targets and a FDA-approved inhibitor, ponatinib with clear anti-liposarcoma activity highlighting its potential therapy for treatment of this deadly tumor.

Original languageEnglish (US)
Article number173
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
StatePublished - Nov 13 2017

Fingerprint

Liposarcoma
Preclinical Drug Evaluations
RNA Interference
Phosphotransferases
Protein-Tyrosine Kinases
Neoplasms
Growth
Cell Line
Cell Cycle Resting Phase
G1 Phase
Disease Management
Cell Cycle Checkpoints
Heterografts
Therapeutics
Clinical Trials
Apoptosis
ponatinib

Keywords

  • Kinase inhibitor
  • Liposarcoma
  • Ponatinib
  • Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Kanojia, D., Garg, M., Martinez, J., Anand, M. T., Luty, S. B., Doan, N. B., ... Koeffler, H. P. (2017). Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. Journal of Hematology and Oncology, 10(1), [173]. https://doi.org/10.1186/s13045-017-0540-x

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. / Kanojia, Deepika; Garg, Manoj; Martinez, Jacqueline; Anand, M. T.; Luty, Samuel B.; Doan, Ngan B.; Said, Jonathan W.; Forscher, Charles; Tyner, Jeffrey; Koeffler, H. Phillip.

In: Journal of Hematology and Oncology, Vol. 10, No. 1, 173, 13.11.2017.

Research output: Contribution to journalArticle

Kanojia, D, Garg, M, Martinez, J, Anand, MT, Luty, SB, Doan, NB, Said, JW, Forscher, C, Tyner, J & Koeffler, HP 2017, 'Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets', Journal of Hematology and Oncology, vol. 10, no. 1, 173. https://doi.org/10.1186/s13045-017-0540-x
Kanojia, Deepika ; Garg, Manoj ; Martinez, Jacqueline ; Anand, M. T. ; Luty, Samuel B. ; Doan, Ngan B. ; Said, Jonathan W. ; Forscher, Charles ; Tyner, Jeffrey ; Koeffler, H. Phillip. / Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. In: Journal of Hematology and Oncology. 2017 ; Vol. 10, No. 1.
@article{006e59ef4dff4de9b0f700fec31e0eb4,
title = "Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets",
abstract = "Background: Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are excellent therapeutic targets. However, very limited knowledge exists of therapeutic critical kinase targets in liposarcoma that could be potentially used in disease management. Methods: Large RNAi and small-molecule tyrosine kinase inhibitor screens were performed against the proliferative capacity of liposarcoma cell lines of different subtypes. Each small molecule inhibitor was either FDA approved or in a clinical trial. Results: Screening assays identified several previously unrecognized targets including PTK2 and KIT in liposarcoma. We also observed that ponatinib, multi-targeted tyrosine kinase inhibitor, was the most effective drug with anti-growth effects against all cell lines. In vitro assays showed that ponatinib inhibited the clonogenic proliferation of liposarcoma, and this anti-growth effect was associated with apoptosis and cell cycle arrest at the G0/G1 phase as well as a decrease in the KIT signaling pathway. In addition, ponatinib inhibited in vivo growth of liposarcoma in a xenograft model. Conclusions: Two large-scale kinase screenings identified novel liposarcoma targets and a FDA-approved inhibitor, ponatinib with clear anti-liposarcoma activity highlighting its potential therapy for treatment of this deadly tumor.",
keywords = "Kinase inhibitor, Liposarcoma, Ponatinib, Therapeutics",
author = "Deepika Kanojia and Manoj Garg and Jacqueline Martinez and Anand, {M. T.} and Luty, {Samuel B.} and Doan, {Ngan B.} and Said, {Jonathan W.} and Charles Forscher and Jeffrey Tyner and Koeffler, {H. Phillip}",
year = "2017",
month = "11",
day = "13",
doi = "10.1186/s13045-017-0540-x",
language = "English (US)",
volume = "10",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

AU - Kanojia, Deepika

AU - Garg, Manoj

AU - Martinez, Jacqueline

AU - Anand, M. T.

AU - Luty, Samuel B.

AU - Doan, Ngan B.

AU - Said, Jonathan W.

AU - Forscher, Charles

AU - Tyner, Jeffrey

AU - Koeffler, H. Phillip

PY - 2017/11/13

Y1 - 2017/11/13

N2 - Background: Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are excellent therapeutic targets. However, very limited knowledge exists of therapeutic critical kinase targets in liposarcoma that could be potentially used in disease management. Methods: Large RNAi and small-molecule tyrosine kinase inhibitor screens were performed against the proliferative capacity of liposarcoma cell lines of different subtypes. Each small molecule inhibitor was either FDA approved or in a clinical trial. Results: Screening assays identified several previously unrecognized targets including PTK2 and KIT in liposarcoma. We also observed that ponatinib, multi-targeted tyrosine kinase inhibitor, was the most effective drug with anti-growth effects against all cell lines. In vitro assays showed that ponatinib inhibited the clonogenic proliferation of liposarcoma, and this anti-growth effect was associated with apoptosis and cell cycle arrest at the G0/G1 phase as well as a decrease in the KIT signaling pathway. In addition, ponatinib inhibited in vivo growth of liposarcoma in a xenograft model. Conclusions: Two large-scale kinase screenings identified novel liposarcoma targets and a FDA-approved inhibitor, ponatinib with clear anti-liposarcoma activity highlighting its potential therapy for treatment of this deadly tumor.

AB - Background: Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease. The Achilles heel of cancer often is their kinases that are excellent therapeutic targets. However, very limited knowledge exists of therapeutic critical kinase targets in liposarcoma that could be potentially used in disease management. Methods: Large RNAi and small-molecule tyrosine kinase inhibitor screens were performed against the proliferative capacity of liposarcoma cell lines of different subtypes. Each small molecule inhibitor was either FDA approved or in a clinical trial. Results: Screening assays identified several previously unrecognized targets including PTK2 and KIT in liposarcoma. We also observed that ponatinib, multi-targeted tyrosine kinase inhibitor, was the most effective drug with anti-growth effects against all cell lines. In vitro assays showed that ponatinib inhibited the clonogenic proliferation of liposarcoma, and this anti-growth effect was associated with apoptosis and cell cycle arrest at the G0/G1 phase as well as a decrease in the KIT signaling pathway. In addition, ponatinib inhibited in vivo growth of liposarcoma in a xenograft model. Conclusions: Two large-scale kinase screenings identified novel liposarcoma targets and a FDA-approved inhibitor, ponatinib with clear anti-liposarcoma activity highlighting its potential therapy for treatment of this deadly tumor.

KW - Kinase inhibitor

KW - Liposarcoma

KW - Ponatinib

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85034056179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034056179&partnerID=8YFLogxK

U2 - 10.1186/s13045-017-0540-x

DO - 10.1186/s13045-017-0540-x

M3 - Article

C2 - 29132397

AN - SCOPUS:85034056179

VL - 10

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 173

ER -